• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Medicaid Redetermination in Oregon and the Partnership Between CareOregon and SCAN Health


President and CEO of CareOregon, Eric Hunter, talks with MHE about what’s on his mind when it comes to healthcare. Throughout the discussion, MHE editors got an idea of how Medicaid redetermination is going for CareOregon, and took a deeper look at the collaboration or “combination” underway between SCAN Health and CareOrgeon.

Q: When you got up this morning and thought about work and healthcare, what was on your mind?

A: At the top of (my mind) every morning is our network, the frailty of the network that we rely on to serve at CareOregon – over half a million people. That's not the system writ large, even for our tiny bit of it. The challenges are immense, and as creative as we want to be in programs, and setting up ways to engage people and get them to a healthier state and in their communities, if we don't have the partners who can make that happen, then we're lost. I think there are a lot of needs out there right now. So the workforce, the ability and availability, that gives them access, whether it's hospitals or dental hygienist or psychiatrist or SUD vendors, transportation across the board, it's really a burden for our members, and one that just makes life so much more difficult than it needs to be for them.

Q: Can you address your collaboration with SCAN Health?

A: We're working with SCAN to create an umbrella organization of sorts. A parent company called Health Right Group of which CareOregon will be of subsidiary and the SCAN Health plans will be subsidiaries and have a shared services division, as well as a ancillary services division.

CareOregon will continue to exist with our name, our mission, our board and our relationship with our communities as we've always had, just as part of a larger organization.

We formally filed with SCAN I think December 31 and we hope that sometime in the late summer, early fall, we can get to closing, but right now the state is doing their due diligence to make sure this combination won't negatively impact Oregonians, particularly Medicaid, Medicaid members, dual members, our providers and our communities.

Related Videos
Video 3 - "In-Office Procedures, Over-the-Counter Options, Treatment Delays, and Costs"
Video 6 - "Safety Analysis and Interpreting Results from MAJIC-PV"
Video 5 - "Key Findings from MAJIC-PV"
Video 2 - "Traditional Treatment of Demodex Blepharitis, FDA approval, and Lotilaner Ophthalmic Solution, 0.25%"
Gabriela Hobbs, MD, an expert on polycythemia vera
Gabriela Hobbs, MD, and Timothy Mok, PharmD, BCPS, BCOP
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Related Content
© 2024 MJH Life Sciences

All rights reserved.